1 / 37

NON INFECTIOUS PERIPHERAL ULCERATIVE KERATITIS [PUK]

NON INFECTIOUS PERIPHERAL ULCERATIVE KERATITIS [PUK]. A Clinical Approach DR. REKHA GYANCHAND Cornea consultant, Lions Eye Hospital BANGALORE. WHAT IS PUK ?. Potentially devastating Crescent shaped Juxtalimbal corneal stromal inflammation epithelial defect

axelle
Download Presentation

NON INFECTIOUS PERIPHERAL ULCERATIVE KERATITIS [PUK]

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. NON INFECTIOUS PERIPHERAL ULCERATIVE KERATITIS [PUK] A Clinical Approach DR. REKHA GYANCHAND Cornea consultant, Lions Eye Hospital BANGALORE

  2. WHAT IS PUK ? • Potentially devastating • Crescent shaped • Juxtalimbal corneal stromal inflammation • epithelial defect • Stromal infiltrate • Progressive stromal melting • If untreated necrosis of entire cornea

  3. WHY IN PERIPHERAL CORNEA ? • Peripheral cornea - Unique anatomical & immunological features • Close to sclera / episclera / conjunctiva • Limbal capillary Arcade • Avascular central cornea • Associated with sub conjunctival lymphaticsafferent arm •  IgM in periphery large •  Langerhans cells • Reservoir of inflammatory cells • More susceptible to immunological damage

  4. PATHOPHYSIOLOGY OF DAMAGE IN PUK Any inflammatory stimulus in peripheral cornea local cellular & humoral response complement activation  vascular permeability  chemotactic factors for neutrophils (C3a , C5a) neutrophil invasion Inflamm Of Conj proteolytic ,collagenolytic enzymes,leucotrienes destruction of collagen Collagenase Corneal thinning

  5. CLINICAL PRESENTATION & DIAGNOSIS • 50% Of non infectious PUK due to collagen vascular disease (SLE, RP, PSS, RA,WG, PAN, GCA) • 34% of non infectious PUK caused by RA (Tauber et al) • PUK may be initial manifestation of WG & PAN • Moorens ulcer – local autoimmune disease with PUK

  6. CLINICAL PRESENTATION &DIAGNOSIS - II • PUK due to CVD more in females • PUK due to Moorens more in males • Other causes include • Neoplasia • Rosaceae • Surgical trauma • Blepharitis • Inflammatory bowel disease

  7. EXAMINATION IN PUK • Ocular • Systemic

  8. OCULAR EXAMINATION Symptoms • Pain, epiphora, photophobia •  pain if scleritis (RA, WG, PAN, RP) •  pain without scleritis ( Mooren’s) • Decreased VA

  9. EXAMINATION Examination of lids • Blepharitis • Telengiectasis (rosaecae) Posterior segment examination • Posterior scleritis • Vasculitis of CVD

  10. SLIT LAMP EXAMINATION-CORNEA • Crescent • Juxta limbal • Epithelial defect • Stromal yellow white infiltrates • Stromal thinning • Circumferential /central spread • Adjacent scleral / conjunctival inflammation

  11. SLIT- LAMP EXAMINATION SCLERA • Associated necrotising scleritis  systemic disease • In advanced cases- corneal/scleral melt

  12. SYSTEMIC EXAMINATION • Thorough systemic history & examination mandatory • Important Questionnaire? • Weight loss, fatigue • Skin – facial rashes, ulcers, periungual infarcts(SLE) • Respiratory symptoms ( WG, SLE) • GI symptoms- pain diarrhoea ( SLE, WG) • Musculoskeletal symptoms- joint pain ( RA, SLE) • Neurological – seizures, Raynauds (WG, RP, SLE) • Genitourinary- hematuria ( PAN, SLE) • Swollen ear lobes (RP, SLE) • Deafness (WG) • Nasal ulcers/ bleeds ( WG) • Saddle nose ( WG, RP)

  13. Differential Diagnosis Of PUK • Other Non Inflammatory Progressive Peripheral Thinning: • Terriens marginal degeneration • Pellucid marginal degeneration

  14. TERRIENS MARGINAL DEGENERATION • Progressive , non inflam. thinning • No symptoms,  V/A • Painless • Corneal epith intact • Begins superiorly • No stromal infiltration • Lipid deposition • Occasional adjacent conjunctival or scleral inflammation present • Can perforate

  15. PELLUCID MARGINAL DEGENERATION • Bilateral,painless • Inferior corneal crescent thinning • Progressive • Clear zone of cornea • Epithelium intact • Adjacent conjunctiva no inflammation • Corneal ectasia above thinning • High against the rule astigmatism • Corneal topography

  16. Laboratory Investigations For Non Infectious PUK • CHEST X-RAY • SINUSES (X-RAY / CT SCAN) • HEPATITIS B,C Ag • CBC • ESR • CRP • URINE ANALYSIS • RF • ANA (SLE/RA) • C ANCA (96% WG) • ANTI-ds DNA(SLE) • C3/C4 LEVELS • CIRCULATING IMMUNE COMPLEXES

  17. LOCAL INVESTIGATIONS • Corneal scraping/culture • Conjunctival biopsy • Removes source of collagen • Diagnosis of CVD fibrinoid necrosis,granulomas,vasculitis • Diagnosis of Moorens justifies immune suppression in occult systemic disease

  18. Treatment of Non Infectious PUK THERAPY MEDICAL SURGICAL LOCAL SYSTEMIC

  19. LOCAL THERAPY Goals • Promote epithelial healing– stromal thinning • Control of inflammation • Collagenase inhibition–  stromal thinning

  20. Promote epithelial healing • Lubricating drops, gels • Avoid epitheliotoxic drugs ( aminoglycosides – tobra, genta; fluroquinolones—ciprofloxacin) • No role of topical antibiotics / antifungals unless secondary infection

  21. Control of inflammation • No role of topical steroids/ NSAIDS • ( inhibits collagen synthesis—increases melt) • Use topical 1% medroxy progesterone • (good anti inflammatory, no collagen synthesis inhibition) • Can use topical cyclosporine 0.5- 1% • ( local T cell immune modulation) • Low dose topical steroids Lid hygeine only in marginal infiltrates with blepharitis ( staph antigen)

  22. Other local medical treatment • Blepharitis: lid hygeine • Rosaecae: erythromycin ointment; metronidazole

  23. SYSTEMIC THERAPY Systemic collagenase inhibitors • Tetracycline 250 mg QID • Doxycycline 100 mg OD • Systemic steroids + cytotoxic immunosuppressives

  24. INDICATIONS FOR IMMUNE SUPPRESSION • PUK associated with proven CVD like RA, PAN, RP, WG, PSS, GCA, Churg-strauss angitis • If PUK associated with necrotising scleritis • If PUK unresponsive to aggressive conventional medical or surgical therapy

  25. DRUGS USED High dose oral prednisolone 1- 1.5 mg / kg BW or Pulsed IV methyl prednisolone ( 0.5- 1g) started first as cytotoxic immunosuppression takes 4 – 6 weeks for action Drug of choice– oral cyclophosphamide ( 2 mg/ kg / day) adjust to clinical response, adverse effects

  26. DRUGS USED • Methotrexate, azathioprine, cyclosporine-A • Methotrexate : DOC in RA ( 7.5- 12.5 mg / wk) • Azathioprine: 1.3 mg/kg/day • Cyclosporine-A:2.5-5mg/kg/day • Monitor CBC,LFT,renal function tests • Role of immunologist important • Good patient education: long term follow up systemic nature of disease

  27. Surgical treatment Tissue adhesives ( cyano acrylate glue ) + BSL • Impending perforation / large thinning/ perforation size < 1-2mm • Delays disease process while patient is on immunosuppressives •  infiltration of inflammatory cells

  28. Surgical treatment • Conjunctival resection + superficial keratectomy + glue + BCL • Removes source of cytokines / inflammatory cells

  29. Tectonic lamellar / full thickness corneal / scleral graft – Large Perforation w/ Uveal Prolapse

  30. Simultaneous systemic immunosuppression very important or graft will also melt

  31. LONG TERM MANAGEMENT Local disease healed • No inflammation • Epithelium intact • Vascularised Corneal pannus

  32. LONG TERM MANAGEMENT • Long term follow up as relapses • Prolonged systemic immune suppression till underlying disease controlled even if EQ • Residual astigmatic correction– increases VA • Combination of LK +PK for visual rehabilitation done with full immunosuppression as surgery can trigger relapse • Cataract surgery when systemic disease under control & under systemic steroids

  33. MOORENS ULCER • Distinct clinical entity in PUK • PUK not associated with CVD • ? Local auto immune disorder (altered corneal Ag) • ? Role of hepatitis C Ag

  34. Distinguishing features • PUK unilateral / bilateral • Pain out of proportion • No scleritis • Typical overhanging central edge • More aggressive and early conjunctival resection and keratectomy advisable

  35. Glue + BCL – if impending perforation & increased thinning Systemic steroids and immuno suppressives only if b/l moorens nonresponsive to local therapy Cyclophosphamide, methotrexate : DOC If Hep C Ag + : interferon alpha 2b ( 3 million units tri weekly SC inj – for 6 months

  36. Conclusion.. • Non Infectious PUK is a potentially devastating disorder, can be the initial presentation of a serious collagen vascular disorder. Hence proper diagnosis and aggressive therapy could improve local and systemic morbidity.

  37. THANK YOU!

More Related